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Abstract
Setting
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB)
and HIV co-infection.
Objective
To describe time to antiretroviral treatment (ART) initiation among HIV-infected RR-TB
patients initiating RR-TB treatment and to assess the association between time to ART initi-
ation and treatment outcomes.
Design
A retrospective cohort study of patients with RR-TB and HIV co-infection not on ART at RR-
TB treatment initiation.
Results
Of the 696 RR-TB and HIV-infected patients initiated on RR-TB treatment between 2009
and 2013, 303 (44%) were not on ART when RR-TB treatment was initiated. The median
CD4 cell count was 126 cells/mm3. Overall 257 (85%) patients started ART during RR-TB
treatment, 33 (11%) within 2 weeks, 152 (50%) between 2–8 weeks and 72 (24%) after 8
weeks. Of the 46 (15%) who never started ART, 10 (21%) died or stopped RR-TB treatment
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within 4 weeks and 16 (37%) had at least 4 months of RR-TB treatment. Treatment success
and mortality during treatment did not vary by time to ART initiation: treatment success was
41%, 43%, and 50% among patients who started ART within 2 weeks, between 2–8 weeks,
and after 8 weeks (p = 0.62), while mortality was 21%, 13% and 15% respectively (p =
0.57). Mortality was associated with never receiving ART (adjusted hazard ratio (aHR) 6.0,
CI 2.1–18.1), CD4 count100 (aHR 2.1, CI 1.0–4.5), and multidrug-resistant tuberculosis
(MDR-TB) with second-line resistance (aHR 2.5, CI 1.1–5.4).
Conclusions
Despite wide variation in time to ART initiation among RR-TB patients, no differences in
mortality or treatment success were observed. However, a significant proportion of patients
did not initiate ART despite receiving >4 months of RR-TB treatment. Programmatic priori-
ties should focus on ensuring all patients with RR-TB/HIV co-infection initiate ART regard-
less of CD4 count, with special attention for patients with CD4 counts 100 to initiate ART
as soon as possible after RR-TB treatment initiation.
Background
The emergence of rifampicin-resistant tuberculosis (RR-TB) challenges the success of national
TB control programs and the survival of patients with the disease [1]. RR-TB, or TB with any
resistance to rifampicin, includes rifampicin mono-resistant tuberculosis, multidrug-resistant
tuberculosis (MDR-TB), and extensively resistant tuberculosis (XDR-TB) [1]. South Africa has
high dual burdens of both RR-TB and human immunodeficiency virus (HIV). In 2013, 26,023
laboratory-confirmed RR-TB cases were reported in South Africa with only 10,663 (41%)
reported to have been initiated on second-line anti-tuberculosis treatment [1]. In 2012 it was
estimated that 6.4 million people (12%) of the total South African population were living with
HIV [2]. According to the 2014 World Health Organization Global TB Report, 62% of all TB
cases in South Africa are co-infected with HIV and only 66% of these received antiretroviral
therapy (ART) during TB treatment [1].
Patients with MDR-TB who are HIV-infected have been reported to have high early mortal-
ity [3,4]. In KwaZulu Natal, South Africa, one year mortality was more than 70%, with 30% of
deaths occurring within 30 days of MDR-TB diagnosis [5]. Prior to widespread ART provision
in South Africa, HIV-infected MDR-TB patients had a two-fold mortality when compared to
HIV uninfected patients [4]. Improved survival was reported more recently from our setting in
Khayelitsha, South Africa, although early mortality remains substantial, particularly among
HIV-infected patients [6]. More rapid provision of ART might be expected to reduce this
excess mortality [7,8].
In KwaZulu Natal, among HIV co-infected XDR-TB patients, provision of ART at any
point during second-line treatment was associated with improved survival, particularly for
patients with CD4 counts 200 cells/mm3 [3]. Similarly, ART provision during treatment was
associated with improved 12-month survival among XDR-TB patients in four provinces across
South Africa [9].
While it is evident that the initiation of ART at some point during RR-TB treatment is bene-
ficial, evidence supporting the optimal time to initiate ART is limited. Second-line treatment
for RR-TB is less well tolerated than first-line TB treatment with higher rates of adverse events
Time to ART after RR-TB Treatment Initiation
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[10,11]. Given the potential for additive toxicity with ART [12], it may be beneficial to delay
ART initiation until second-line TB treatment is tolerated.
Current clinical guidelines in South Africa regarding the appropriate time to initiate ART
are primarily based on data from patients with drug-susceptible TB [13–15]. In these random-
ized trials, ART initiation within 2–4 weeks was associated with improved survival in those
patients with low CD4 counts (<50 cells/mm3). Since 2008, most TB and HIV guidelines have
recommended ART for all RR-TB patients within South Africa. There is, however, a lack of
consensus with respect to timing of ART initiation for RR-TB patients (Table 1).
Guidance for ART initiation is available in the 2013 South African National Drug-Resistant
TB guidelines and the 2013 South African ART guidelines [16,17]. The National Drug-Resis-
tant TB guidelines provide conflicting information; firstly they state that the optimal time to
ART is not known and that ART initiation depends on a careful calculation of risk and benefits
for each patient [16]. However, the guidelines advise that all HIV-infected TB patients, includ-
ing RR-TB patients, are eligible for ART initiation irrespective of CD4 cell count, and should
be “fast-tracked” for ART initiation within 2 weeks of being eligible; eligibility criteria are not
explicitly outlined. Thereafter, they suggest that ART be started within the first month of
RR-TB treatment or when RR-TB treatment is tolerated [16]. In contrast the 2013 South Afri-
can ART guidelines suggest ART “fast-tracking” (within 7 days) for all TB patients with
CD4< 50 cells/mm3 [17]; for the remainder, these guidelines suggest 2–8 weeks of TB therapy
before commencing ART [17]. The inconsistencies across national guidelines are likely to lead
to uncertainty amongst clinicians regarding appropriate time for ART initiation among RR-TB
patients, along with the potential for significant delays and missed opportunities for ART initi-
ation in co-infected patients.
Due to the lack of direct evidence regarding the timing of ART initiation for RR-TB
patients, we aimed to describe time to ART initiation among RR-TB patients in a community-
based RR-TB programme in Khayelitsha, Cape Town. Additionally, we aimed to assess associa-
tions between time to ART initiation and the patient outcomes of treatment success and
mortality.
Methods
Ethical approval
Ethical approval was received from the University of Cape Town Human Research Ethics
Committee (540/2010) for the evaluation of the decentralized programme. Additional ethical
approval specific to this study was received from the Ethics Advisory Group of the Interna-
tional Union against Tuberculosis and Lung Disease, Paris, France and the MSF Ethics Review
Board, Geneva, Switzerland. All routine programme data used for analysis was anonymized
and de-identified as informed consent was not required for this retrospective cohort study.
Design
We conducted a retrospective cohort study of HIV-infected RR-TB patients not on ART at ini-
tiation of second-line anti-tuberculosis treatment. Our outcome measurements were time to
ART initiation and RR-TB treatment outcomes.
Setting and population
The study was conducted in Khayelitsha, the largest township in South Africa’s Western Cape
Province, where government health services in collaboration with Médecins Sans Frontières
developed a decentralized model of RR-TB care. This decentralized model was integrated into
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Table 1. South African guidelines and recommendations for antiretroviral treatment (ART) initiation for drug sensitive- and rifampicin-resistant
tuberculosis patients 2008–2014.
Year Source Recommendation
2008 Guidelines–Antiretroviral therapy in adults:
Southern African HIV Clinicians Society. [21]
TB diagnosed before starting ART
CD4 count <200: commence ART after it is clear that the patient’s TB symptoms are
improving and that TB therapy is tolerated (between 2 and 8 weeks).
CD4 count 200–350: delay ART until after the intensive phase of TB therapy (2
months) unless the patient has other serious HIV-related illness.
CD4 count >350: defer ART.
No speciﬁc recommendation for RR-TB
2009 Draft: Management of drug-resistant tuberculosis:
policy guidelines. SANDOH. [22]
Initiation of ART at the earliest opportunity is encouraged
If CD4 count 350 and no other HIV-related symptoms: Start DRTB treatment. Assess
the need for ART after completing treatment, using CD4 and clinical criteria.
If CD4 count <350: Delay ART until after 1 month of DR-TB treatment.
If CD4 count of <50/ mm3 or presence of other serious HIV illness: Introduce ART as
soon as the patient is stabilized on DR-TB treatment, preferably within the ﬁrst month.
2009 SA National Tuberculosis Management
Guidelines. SANDOH. [23]
TB diagnosed before starting ART
CD4 count 50–200: Delay ART for two months (until intensive phase of TB therapy
complete).
CD4 count of <50 or other serious HIV illness: Introduce ART regimen above as soon
as the client is stabilized on TB therapy (at least 2 weeks between starting TB therapy
and starting ART).
No speciﬁc recommendation for RR-TB
2010 The South African antiretroviral treatment
guidelines. SANDOH. [24]
Require fast track (i.e. ART initiation within 2 weeks of being eligible–MDR-/XDR-TB
irrespective of CD4 count.
2011 Management of Drug-resistant tuberculosis: policy
guidelines. SANDOH. [28]
The National guidelines on the use of antiretroviral therapy need to be
considered in conjunction with the content of this chapter
All HIV positive, MDR- and XDR-TB patients are eligible to start ART irrespective of
CD4 cell count. Moreover, these patients must be fast-tracked (ART initiation within
2 weeks of being eligible) for the initiation of ART.
All patients must be started on ART irrespective of CD4 cell count. Moreover the
initiation of ART must be fast tracked as soon the DR-TB treatment is tolerated
preferably within ﬁrst month of treatment
2012 Guidelines–Antiretroviral therapy in adults:
Southern African HIV Clinicians Society. [38]
Starting ART in patients with TB: Decisions regarding the timing of ART in patients
with TB should be made on the basis of the CD4 count:
CD4 count 50: ART should be regarded as urgent, and the aim should be to start
therapy after 2 weeks of TB treatment.
CD4 count >50: ART should be delayed until after the intensive phase of TB treatment
(2 months) unless the patient has other serious HIV-related conditions (e.g. Kaposi’s
sarcoma or HIV encephalopathy.
No speciﬁc recommendation for RR-TB
2013 The South African antiretroviral treatment
guidelines, SANDOH. [17]
Starting ART in patients with TB
ART indicated irrespective of CD4 count: All types of TB (In patients with TB/HIV drug
resistant or sensitive TB, including extra pulmonary TB).
Patients with TB/HIV co morbidity with CD4 count <50 require fast track (i.e. ART
initiation within 7 days of being eligible).
In general, ART should be initiated as soon as the patient is tolerating their TB
therapy.
January
2013
Management of Drug-resistant tuberculosis: policy
guidelines, updated. SANDOH. [16]
All HIV-positive TB, MDR- and XDR-TB patients are eligible to start ART irrespective
of CD4 cell count. Furthermore, these patients must be fast-tracked (ART initiation
within 2 weeks of being eligible) for the initiation of ART.
(Continued)
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the existing national TB program in 2008 and handed over to government for management in
2011 [6,18]. Khayelitsha has among the highest burdens of TB, including RR-TB, and HIV
infection in the country and globally. In 2011, HIV antenatal prevalence was estimated to be
37% and the TB case notification rate was at least 1,500 per 100,000 people a year. More than
200 RR-TB patients are diagnosed every year, of which 70% are HIV co-infected [6,18,19].
RR-TB diagnosis and treatment services are provided through 10 primary health care clinics
and one secondary level hospital; integrated TB and HIV services are offered to a target popula-
tion of an estimated 400,000 people, half of whom live in informal settlements [20].
Diagnosis, registration, and treatment initiation for RR-TB was conducted according to the
National Drug-Resistant TB guidelines at the time of the study. All patients diagnosed with
RR-TB started on a standardized second- line TB treatment regimen, with subsequent adjust-
ment of treatment if any second-line drug resistance was detected. At the start of the study
period in 2009, the treatment regimen in Khayelitsha included ofloxacin, kanamycin, ethambu-
tol, ethionamide, and pyrazinamide. Cycloserine was added from September 2009, and was
replaced by terizidone in April 2010; ofloxacin was also replaced by moxifloxacin in September
2009. Since 2008, all HIV-infected RR-TB patients have been eligible for ART, regardless of
CD4 count; the aim has been to initiate ART as soon as possible, but no specific guidance was
available on the timing of ART. First-line ART included zidovudine (or stavudine), lamivudine,
and efavirenz (or nevirapine) [16,17,21–25]. More recently, tenofovir became one of the pre-
ferred non-nucleoside reverse transcriptase inhibitor options, but was mostly avoided during
aminoglycoside treatment [16,17]. Patients received individual structured RR-TB counselling
as well as HIV counselling and testing at diagnosis and start of RR-TB treatment. The study
included all RR-TB and HIV co-infected patients starting RR-TB treatment in Khayelitsha
between January 2009 and December 2013 who were not on ART at the time of RR-TB treat-
ment initiation.
Data variables, sources, and statistical analysis
Data was sourced from the Khayelitsha RR-TB database and cross checked with medical rec-
ords for confirmation of data specific to this study. The Khayelitsha RR-TB database was
Table 1. (Continued)
Year Source Recommendation
2014 Guidelines–Antiretroviral therapy in adults:
Southern African HIV Clinicians Society. [39]
Starting ART in patients with TB: Decisions regarding the timing of ART in patients
with TB should be made on the basis of the CD4 count:
CD4 count 50: ART should be regarded as urgent, with the aim to start therapy 2
weeks following the commencement of TB treatment.
CD4 count >50: ART can be delayed until 8 weeks after starting TB treatment, but no
later. However, if the patient has other WHO stage 4 conditions, ART should also be
initiated 2 weeks after TB treatment is started.
No speciﬁc recommendation for RR-TB
2014 National Tuberculosis Management Guidelines,
SANDOH. [40]
TB diagnosed before ART
Patients with CD4 count <50: Fast track- start ART within 2 weeks after starting TB
treatment.
Patients with CD4 count >50: Start ART 2–8 weeks after starting TB treatment.
Patients with TB meningitis (irrespective of CD4 count: Defer ART until 8 weeks after
starting TB treatment
No speciﬁc recommendation for RR-TB
SANDOH: South African National Department of Health
doi:10.1371/journal.pone.0142873.t001
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established in 2008 for evaluation of the decentralized model of care and all data was collected
prospectively from 2008 [6]. The STROBE guidelines on the reporting for observational studies
were followed [26]. Data meeting the inclusion criteria were extracted into an Excel database
(Microsoft, Redmond, WA, USA). CD4 count was defined as CD4 result available at time at
RR-TB diagnosis or within one month of RR-TB treatment start. Final RR-TB treatment out-
comes were defined according to the South African National Guidelines, which are in line with
the World Health Organization outcome definitions, with the exception of treatment failure,
where failure to convert positive cultures to negative within 6–8 months constitutes failure of
treatment [22,27,28]. The time from RR-TB treatment start to start of ART was calculated in
days and then categorised as 2 weeks, 2–8 weeks and> 8 weeks; time windows were derived
from the guidelines described in Table 1.
Data was analysed using STATA/IC 12 software (Stata Corp, College Station, TX, USA) and
descriptive statistics were used to report demographic, clinical, and immunological characteris-
tics of patients. Final treatment outcome proportions were compared by chi-square tests; a p–
value< 0.05 was considered significant. Time to ART initiation was shown using a Kaplan
Meier curve. To assess the impact of time to ART initiation on mortality, a multivariate Cox
regression analysis was performed. Censoring for both analyses was done at loss from RR-TB
treatment (previously defined as lost to follow-up) and transfer out. Data was administratively
censored as of 30 June 2014, when the analysis was conducted. Factors significant (p<0.05)
from univariate analysis and those previously determined to be associated with mortality
among RR-TB patients were included in the model.
Results
During the study period between January 2009 to December 2013, 982 laboratory-confirmed
RR-TB patients from Khayelitsha initiated second-line RR-TB treatment. Among these, 71%
(696/982) were HIV positive and 56% (393/696) of these were on ART at start of RR-TB treat-
ment, leaving 303 RR-TB and HIV positive patients not on ART at the time of starting second-
line TB treatment for inclusion in the analysis. Demographic, clinical, and immunological
characteristics are shown in Table 2. The median CD4 count was 126 cells/mm3 and 152 (41%)
had a CD4 count100 cells/mm3.
Overall 257 (85%) of patients were recorded as initiating ART; 33 (11%) started ART within
2 weeks, 152 (50%) within 2–8 weeks, and 72 (24%) started after 8 weeks (Table 2). Time to
ART initiation is shown in a Kaplan-Meier graph (Fig 1). Of all those patients who initiated
ART, respectively, 35%, 65%, and 75% of patients had been initiated on ART at 30, 60, and
90 days.
Among the 46 patients who never initiated ART, nine (20%) died, one experienced loss
from treatment, and three were transferred out within 4 weeks of starting second-line treat-
ment. Among the nine patients with early mortality and no ART, four (44%) had CD4 counts
less than 100 cells/mm3. At 8 weeks post RR-TB treatment initiation, 28 patients known to be
in clinical care and eligible for ART (median CD4 count 116 cells/mm3) were not yet initiated;
by 16 weeks, 16 patients remaining in care and eligible (median CD4 count 132 cells/mm3)
were still not initiated on ART. At 6 months after RR-TB treatment initiation, 66% of the 12
patients remaining in care but not initiated on ART had already converted their positive spu-
tum cultures to negative, indicating good retention in care and representing a missed opportu-
nity to initiate ART in a timely fashion.
Final 24 month treatment outcomes were available for 229 (76%) of patients started on
treatment before June 2013. Among patients initiating ART, there was no significant associa-
tion between time to ART initiation and final RR-TB treatment outcomes (Table 3). Treatment
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Table 2. Demographic, clinical and immunological characteristics of patients starting treatment for rifampicin-resistant tuberculosis in patients
co-infected with HIV not receiving antiretroviral treatment, in Khayelitsha, South Africa 2009–2013.
Variable ART Starteda
2 weeks 2–8 weeks >8 weeks Never Total
n (%) n (%) n (%) n (%)
Total 33 (11) 152 (50) 72 (24%) 46 (15) 303 (100)
Median time(weeks) (IQR) 1.5 (1–2) 4 (3–6) 15 (10–20)
Gender
Male 12 (36) 70 (46) 30 (42) 26 (57) 138 (46)
Female 21 (64) 82 (54) 42 (58) 20 (43) 165 (54)
Age group (years)
0–25 5 (15) 26 (17) 16 (22) 7 (15) 54 (18)
26–30 8 (24) 39 (26) 10 (14) 7 (15) 64 (21)
31–35 4 (12) 32 (21) 18 (25) 11 (24) 65 (21)
36–40 7 (21) 31 (20) 13 (18) 13 (28) 64 (21)
41+ 9 (28) 24 (16) 15 (21) 8 (18) 56 (19)
Median age (IQR) 33 (27–41) 32 (28–37) 33 (26–39) 24 (29–40) 33 (18–55)
TB treatment status
New 11 (33) 62 (41) 26 (36) 15 (33) 114 (37)
Retreatment 22 (67) 90 (59) 46 (67 30 (65) 188 (62)
Unknown 0 (0) 0 (0) 0 (0) 1 (2) 1 (0)
CD4 count (cells/mm3)
0–100 16 (49) 69 (45) 18 (25) 22 (48) 125 (41)
100–200 9 (27) 38 (25) 11 (15) 9 (19) 67 (22)
200–300 3 (9) 21 (14) 11 (15) 7 (15) 42 (14)
>300 5 (15) 24 (16) 32 (45) 8 (18) 69 (23)
Median cd4 (IQR) 101 (38–153) 111 (48–217) 274 (106–460) 112 (52–229) 126 (54–280)
RR-TBb proﬁle
R-monoc 7 (21) 22 (14) 20 (28) 11 (24) 60 (20)
GXP RRd only 1 (3) 6 (4) 2 (3) 1 (2) 10 (3)
MDRe 21 (64) 105 (69) 48 (66) 28 (61) 202 (67)
MDR+SLDresf 4 (12) 19 (13) 2 (3) 6 (13) 31 (10)
Type of TB disease
Smear positive PTBg 13 (39) 65 (43) 36 (50) 19 (41) 133 (44)
Smear negative PTBg 17 (52) 73 (48) 33 (47) 21 (46) 144 (48)
EPTBh 2 (6) 6 (4) 1 (1) 2 (4) 11 (4)
Both PTBg & EPTBf 1 (3) 4 (3) 1 (1) 0 (0) 6 (2)
Unknown 0 (0) 4 (3) 1 (1) 4 (9) 9 (3)
Site of treatment initiation
Primary carek 23 (70) 124 (81) 63 (88) 31 (67) 241 (80
Khayelitsha district hospital 0 (0) 7 (5) 3 (4) 3 (7) 13 (4)
Tertiary hospital outside Khayelitsha 10 (10) 21 (14) 6 (8) 6 (26) 49 (16)
Year started treatment
2009 8 (9) 23 (26) 28 (31) 14 (34) 73
2010 7 (12) 26 (46) 15 (26) 9 (16) 57
2011 6 (10) 33 (55) 13 (22) 8 (13) 60
2012 8 (23) 36 (60) 7 (12) 9 (25) 60
(Continued)
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Table 2. (Continued)
Variable ART Starteda
2 weeks 2–8 weeks >8 weeks Never Total
n (%) n (%) n (%) n (%)
2013 4 (8) 34 (64) 9 (17) 6 (11) 53
Percent (column)
aART: Antiretroviral treatment
bRR-TB: Rifampicin-resistant tuberculosis
cR-mono: Rifampicin mono resistance
dGXP: Gene-Xpert MTB/RIF rifampicin resistance only
eMDR: Multi-drug resistant tuberculosis with no conﬁrmed second-line resistance
fSLDres: second-line drug resistance
gPTB: Pulmonary TB
hEPTB: Extra-pulmonary TB
kPrimary care: treatment initiation at clinic and local sub-acute care facility
Percent (Row)
Year RR-TBb treatment started
doi:10.1371/journal.pone.0142873.t002
Fig 1. Kaplan-Meier plot of time to antiretroviral treatment initiation for HIV infected rifampicin resistant tuberculosis patients.
doi:10.1371/journal.pone.0142873.g001
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success was 41%, 43%, and 50% in patients who started ART within 2 weeks, between 2 to 8 weeks,
and after 8 weeks respectively (p = 0.62). Patients who never started ART had a RR-TB treatment
success rate of only 6% (p<0.01 compared to ever starting ART). Similarly, mortality during treat-
ment was 21%, 13%, and 15% among patients who started ART within 2 weeks, between 2–8
weeks, and after 8 weeks(p = 0.57). However, 41% of patients who never initiated ART died during
RR-TB treatment (p<0.01 compared to patients receiving ART). Of the 16 patients still on treat-
ment without ART at four months, only two were successfully treated; two died, eight experienced
loss from treatment, one failed treatment, one was transferred out with unknown outcome, and
the remaining two were still receiving RR-TB treatment at time of analysis.
On univariate analysis of time to death, mortality was significantly associated with not
receiving ART, CD4 count<100 cells/mm3, and MDR-TB with either fluoroquinolone or sec-
ond-line injectable resistance (Table 4). In the multivariate model, these factors remained sig-
nificant. There were no significant differences in survival over six months between patients
initiated on ART within 2 weeks, 2–8 weeks, and>8 weeks (Fig 2).
Discussion
Due to a paucity of data on optimal timing of ART initiation in the treatment of RR-TB, cur-
rent and past guidelines concerning time to ART initiation for HIV-infected RR-TB patients in
South Africa lack clarity and consensus (Table 1). Our findings show that there was a wide var-
iation in time to ART initiation in Khayelitsha, and there were a significant proportion of
patients that never started ART despite significant opportunity to do so. Among those initiated
on ART there was no significant difference in either treatment success or mortality stratified by
time to ART initiation.
Our data demonstrate that patients who never initiated ART have high mortality and poor
outcomes overall. A small proportion of these patients died or experienced loss from treatment
very rapidly after starting second-line treatment, therefore the opportunity to start ART may
Table 3. Treatment outcomes by time to initiation of antiretroviral therapy of patients with rifampicin-resistant tuberculosis in Khayelitsha, South
Africa, January 2009 –September 2012 (N = 229).
Time to ARTa initiation
Treatment Outcome 2 weeks 2–8 weeks >8 weeks Never startedARTa Total P valueb
n (%) n (%) n (%) n (%) n (%)
Treatment Successc 12 (41) 45 (43) 30 (50) 2 (6) 89 (39) 0.624
Loss from treatmentd 8 (28) 27 (26) 15 (25) 13 (36) 63 (28) 0.948
Diedc 6 (21) 14 (13) 9 (15) 15 (41) 44 (19) 0.570
Treatment failuref 0 (0) 3 (3) 3 (5) 1 (3) 7 (3) 0.613
Not evaluatedg 3 (10) 15 (14) 3 (5) 5 (14) 26 (11) 0.177
Total 29 (100) 104 (100) 60 (100) 36 (100) 229(100)
Percent (column)
*The denominator, 229, for all patients having ﬁnal treatment outcome; 24 months after starting second-line treatment.
aART: Antiretroviral treatment.
bP-value is for Fisher’s exact test for categorical values(2 weeks, 2–8 weeks and >8 weeks).
cTreatment Success: The sum of cured and treatment completed.
dLoss from treatment: A patient whose RR-TB treatment was interrupted for 2 consecutive months or more
eDied: A patient who died (all causes) during the course of treatment
fTreatment failure: Treatment terminated or need for permanent regimen change of at least two anti-TB drugs
gNot evaluated: Patients transferred to another facility to receive treatment.
doi:10.1371/journal.pone.0142873.t003
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have been limited. However, the remainder suggest that ART initiation was either overlooked
or not considered at all and is particularly concerning. While efforts have been directed at
improving integration of TB and HIV services, the lack of fully integrated services is often a
primary reason that RR-TB patients are not initiated on ART in a timely fashion [29,30].
Table 4. Cox proportional hazardsmodel of factors associated with time to death in rifampicin-resistant tuberculosis in patients co-infected with
HIV and not on antiretroviral treatment at rifampicin-resistant treatment start, in Khayelitsha, South Africa, 2009–2013.
Factor Univariate Multivariate
HRg (95% CI) P valueh Adjusted HRg (95% CI) P
valueh
Female 0.96 (0.6–1.6) 0.86
Age
0–25 1.0 (Reference)
26–30 0.85 (0.36–1.9) 0.69
31–35 0.88 (0.4–1.9) 0.75
36–40 0.64 (0.3–1.5) 0.3
41+ 1.0 (0.5–2.2) 0.99
Time to ARTa
<2 weeks 1.0 (Reference)
2–8 weeks 0.93 (0.3–2.7) 0.89 0.85 (0.3–2.5) 0.76
8+ weeks 0.94 (0.3–2.9) 0.91 1.2 (0.4–3.9) 0.75
No ART 5.9 (2.0–17.5) <0.01 6.0 (2.0–18.1) <0.01
CD4 count
0–100 2.2 (1.1–4.4) 0.031 2.1 (1.0–4.5) 0.047
100–200 1.2 (0.5–2.8) 0.71 1.21 (0.5–3.1) 0.69
200–300 0.82 (0.3–2.4) 0.72 0.80 (0.3–2.4) 0.68
300+ 1.0 (Reference)
RR-TBb proﬁle
R-monoc 1.0 (Reference)
GXP RRd only 0.42 (0.1–3.1) 0.39 0.40 (0.1–3.2) 0.39
MDRe 0.63 (0.3–1.1) 0.14 0.82 (0.4–1.6) 0.55
MDR+SLDresf 2.1 (1.0–4.5) 0.049 2.5 (1.1–5.4) 0.021
Previous TB treatment (any) 1.8 (1.0–3.1) 0.051 1.8 (1.0–3.5) 0.059
Year RR-TBb treatment started
2009 1.0 (0.5–2.1) 0.97 0.55 (0.2–1.2) 0.14
2010 0.60 (0.2–1.5) 0.26 0.47 (0.2–1.3) 0.13
2011 0.65 (0.3–1.5) 0.31 0.54 (0.2–1.4) 0.18
2012 0.64 (0.3–1.5) 0.30 0.60 (1.0–3.5) 0.25
2013 1.0 (Reference)
Percent (column)
aART: Antiretroviral treatment
bRR-TB: Rifampicin-resistant tuberculosis
cR-mono: Rifampicin mono resistance
dGXP: Gene-Xpert MTB/RIF rifampicin resistance only
eMDR: Multi-drug resistant tuberculosis with no conﬁrmed second-line resistance
fSLDres: second-line drug resistance
gHR: Hazard ratio
hP value
doi:10.1371/journal.pone.0142873.t004
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Additionally, a small number of these patients were started on treatment in hospital settings
and later discharged to continue treatment in the primary care setting. For these patients, con-
tinuity of care, including ART initiation, may have been compromised. Also, it is possible that
some patients refused ART, particularly those with relatively high CD4 counts.
In the absence of evidence-based guidance, clinicians in Khayelitsha are likely to have used
clinical judgement on timing of ART initiation among HIV infected RR-TB patients. Delays in
ART initiation may have been driven by the occurrence of adverse events related to second-
line treatment, particularly in the first month of treatment [10,11]. Other reasons may include
concerns regarding pill burden and the impact on treatment adherence, or the risk of immune
reconstitution inflammatory syndrome; patients with early ART are at more risk of developing
TB-immune reconstitution inflammatory syndrome than patients with delayed ART [31–33].
In this study setting, medical records were not detailed enough to assess potential reasons for
delaying ART, if this was a conscious decision by clinicians.
Overall treatment outcomes were poor, with only 39% treatment success. This is, however,
comparable with national and globally reported outcomes for RR-TB programmes and recently
published RR-TB/HIV co-infected patient cohort studies [1,34]. Inadequate treatment out-
comes result from poorly efficacious and lengthy RR-TB treatment regimens, along with high
rates of loss from treatment reported internationally, in South Africa, and within the Khayelit-
sha RR-TB programme [1,6,34,35].
Rapid ART initiation within two to four weeks appears to be beneficial for patients with low
CD4 counts, but may not be necessary for all patients [13–15,33]. In the SAPIT trial (drug- sus-
ceptible TB patients), there was no difference in overall mortality between patients who started
Fig 2. Kaplan-Meier plot of survival during treatment of rifampicin resistant tuberculosis by ART initiation, frommultivariate Cox regression
analysis for HIV co-infected patients.
doi:10.1371/journal.pone.0142873.g002
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ART within four weeks of TB treatment initiation and those starting ART after two months of
TB therapy. However, there was a survival benefit among patients with CD4 counts50 cells/
mm3 who initiated ART within four weeks [13,33]. Similar findings were demonstrated by
Havlir et al [14]. Overall, there was no significant difference in the proportion of patients with
an AIDS-defining illness or death between those started on ART within two weeks and those
started between eight to twelve weeks after TB treatment. There was, however, a significant dif-
ference among patients with CD4 counts50 cells/mm3 [14]. In the Cambodian CAMELIA
trial, where the median CD4 count at drug-susceptible TB treatment start was less than 50
cells/mm3, there was a significant impact on mortality when ART was initiated two weeks after
TB treatment compared to eight weeks [15].
Information regarding time to ART initiation for RR-TB patients is very limited, with only
one sub-study of the SAPIT trial with 23 patients, assessing the impact of time to ART initia-
tion for MDR-TB patients on survival with 14 patients in the combined integrated arm (ART
within 12 weeks of anti-tuberculosis treatment) and nine in the sequential treatment arm
(ART on completion of anti-tuberculosis drugs) [8]. In this trial starting ART early (within 12
weeks) led to a 86% reduction in mortality, whether or not patients were later switched to sec-
ond-line treatment [8].A Lesotho cohort of HIV infected MDR-TB patients showed 62% suc-
cess rate for ART initiation at a median of 16 days, although no comparison was made with
delayed treatment initiation [7].
Our findings are consistent with those from studies of drug-susceptible TB, and suggest that
delaying ART in this cohort of HIV-infected RR-TB patients, even beyond two months, does
not markedly impact mortality or treatment success [13–15]. However, in our observational
study the association is likely confounded by several factors. Clinicians may have based deci-
sions on when to start ART on the clinical condition of the patient, which is known to be asso-
ciated with outcomes, particularly mortality [36,37]. The direction of this association is
difficult to predict, since life-saving ART may have been started more rapidly among cases
with a high likelihood of poor outcomes, including very low CD4 counts. Patients who were
previously treated for TB also had a tendency for decreased survival, potentially reflecting lon-
ger disease duration and worse clinical condition. While there appeared to be variation in sur-
vival by year of treatment initiation, this was not significant and therefore did not reflect the
impact of changes in guideline recommendations over the study period.
In addition to the lack of documentation on reasons for timing of ART initiation, this study
had limitations associated with the use of routine medical records. The study would be
strengthened if data on the reasons for early or delayed ART initiation, particularly patient
refusal to take ART, as well as information on previous ART history, were available. Unfortu-
nately, medical records were not detailed enough to provide such information. Nonetheless,
this was a large cohort of co-infected patients with treatment decisions reflective of routine
clinical care. Given the limited number of studies assessing the impact of time to ART initiation
on RR-TB patient outcomes, this study provides some additional evidence to guide clinicians
regarding management of these patients.
Conclusions
The findings of this analysis coincide with previous studies that show rapid (within 2 weeks)
ART initiation for patients with low CD4 counts less than or equal to 100 cells/mm3 is crucial
given their high early mortality rates. In addition, our results reaffirm that ART initiation is
required for all RR-TB patients regardless of CD4 count due to high mortality and poor out-
comes among those patients never initiated on ART. The optimal timeframe of ART initiation
in the first weeks to months of RR-TB treatment remains unclear, and will likely continue to be
Time to ART after RR-TB Treatment Initiation
PLOS ONE | DOI:10.1371/journal.pone.0142873 November 10, 2015 12 / 15
debated amongst clinicians trying to treat this complex and high risk group of patients; the
desire for timely immune restoration is unfortunately tempered by pill burden, drug interac-
tions, and frequent toxicities of currently available drugs and RR-TB treatment regimens.
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